However, BRAFi, such as vemurafenib, dabrafenib, and encorafenib, primarily used to treat BRAF-mutated cancers, particularly melanoma, have been found to have unintended off-target effects on endothelial cells, leading to significant vascular complications (140). This evidence concerns the gene BRAF and melanoma.